Literature DB >> 29437627

Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Zofia Bakuła1, Magdalena Modrzejewska1, Lian Pennings2, Małgorzata Proboszcz3, Aleksandra Safianowska3, Jacek Bielecki1, Jakko van Ingen2, Tomasz Jagielski4.   

Abstract

Very few studies have examined drug susceptibility of Mycobacterium kansasii, and they involve a limited number of strains. The purpose of this study was to determine drug susceptibility profiles of M. kansasii isolates representing a spectrum of species genotypes (subtypes) with two different methodologies, i.e., broth microdilution and Etest assays. To confirm drug resistance, drug target genes were sequenced. A collection of 85 M. kansasii isolates, including representatives of eight different subtypes (I to VI, I/II, and IIB) from eight countries, was used. Drug susceptibility against 13 and 8 antimycobacterial agents was tested by using broth microdilution and Etest, respectively. For drug-resistant or high-MIC isolates, eight structural genes (rrl, katG, inhA, embB, rrs, rpsL, gyrA, and gyrB) and one regulatory region (embCA) were PCR amplified and sequenced in the search for resistance-associated mutations. All isolates tested were susceptible to rifampin (RIF), amikacin (AMK), co-trimoxazole (SXT), rifabutin (RFB), moxifloxacin (MXF), and linezolid (LZD) according to the microdilution method. Resistance to ethambutol (EMB), ciprofloxacin (CIP), and clarithromycin (CLR) was found in 83 (97.7%), 17 (20%), and 1 (1.2%) isolate, respectively. The calculated concordance between the Etest and dilution method was 22.6% for AMK, 4.8% for streptomycin (STR), 3.2% for CLR, and 1.6% for RIF. For EMB, INH, and SXT, not even a single MIC value determined by one method equaled that by the second method. The only mutations disclosed were A2266C transversion at the rrl gene (CLR-resistant strain) and A128G transition at the rpsL gene (strain with STR MIC of >64 mg/liter). In conclusion, eight drugs, including RIF, CLR, AMK, SXT, RFB, MXF, LZD, and ethionamide (ETO), showed high in vitro activity against M. kansasii isolates. Discrepancies of the results between the reference microdilution method and Etest preclude the use of the latter for drug susceptibility determination in M. kansasii Drug resistance in M. kansasii may have different genetic determinants than resistance to the same drugs in M. tuberculosis.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium kansasii; drug resistance; molecular resistance; susceptibility testing

Mesh:

Substances:

Year:  2018        PMID: 29437627      PMCID: PMC5913922          DOI: 10.1128/AAC.01788-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece.

Authors:  Zoe Gitti; Elpis Mantadakis; Sofia Maraki; George Samonis
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

2.  Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey.

Authors:  Caroline Taillard; Gilbert Greub; Rainer Weber; Gaby E Pfyffer; Thomas Bodmer; Stefan Zimmerli; Reno Frei; Stefano Bassetti; Peter Rohner; Jean-Claude Piffaretti; Enos Bernasconi; Jacques Bille; Amalio Telenti; Guy Prod'hom
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

3.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.

Authors:  Remedios Guna; Carlos Muñoz; Victoria Domínguez; Angeles García-García; Jorge Gálvez; Jesús-Vicente de Julián-Ortiz; Rafael Borrás
Journal:  J Antimicrob Chemother       Date:  2005-04-11       Impact factor: 5.790

5.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria.

Authors:  F Alcaide; G E Pfyffer; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

6.  Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea.

Authors:  Hum Nath Jnawali; Heekyung Yoo; Sungweon Ryoo; Kwang-Jun Lee; Bum-Joon Kim; Won-Jung Koh; Chang-Ki Kim; Hee-Jin Kim; Young Kil Park
Journal:  World J Microbiol Biotechnol       Date:  2013-01-18       Impact factor: 3.312

7.  In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands.

Authors:  Jakko van Ingen; Tridia van der Laan; Richard Dekhuijzen; Martin Boeree; Dick van Soolingen
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

8.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Authors:  Wouter Hoefsloot; Jakko van Ingen; Claire Andrejak; Kristian Angeby; Rosine Bauriaud; Pascale Bemer; Natalie Beylis; Martin J Boeree; Juana Cacho; Violet Chihota; Erica Chimara; Gavin Churchyard; Raquel Cias; Rosa Daza; Charles L Daley; P N Richard Dekhuijzen; Diego Domingo; Francis Drobniewski; Jaime Esteban; Maryse Fauville-Dufaux; Dorte Bek Folkvardsen; Noel Gibbons; Enrique Gómez-Mampaso; Rosa Gonzalez; Harald Hoffmann; Po-Ren Hsueh; Alexander Indra; Tomasz Jagielski; Frances Jamieson; Mateja Jankovic; Eefje Jong; Joseph Keane; Wo-Jung Koh; Berit Lange; Sylvia Leao; Rita Macedo; Turid Mannsåker; Theodore K Marras; Jeannette Maugein; Heather J Milburn; Tamas Mlinkó; Nora Morcillo; Kozo Morimoto; Dimitrios Papaventsis; Elia Palenque; Mar Paez-Peña; Claudio Piersimoni; Monika Polanová; Nalin Rastogi; Elvira Richter; Maria Jesus Ruiz-Serrano; Anabela Silva; M Pedro da Silva; Hulya Simsek; Dick van Soolingen; Nora Szabó; Rachel Thomson; Teresa Tórtola Fernandez; Enrico Tortoli; Sarah E Totten; Greg Tyrrell; Tuula Vasankari; Miguel Villar; Renata Walkiewicz; Kevin L Winthrop; Dirk Wagner
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

9.  Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.

Authors:  C H Ahn; R J Wallace; L C Steele; D T Murphy
Journal:  Am Rev Respir Dis       Date:  1987-01

10.  The drug resistance profile of Mycobacterium abscessus group strains from Korea.

Authors:  Seung Heon Lee; Hee Kyung Yoo; Seol Hee Kim; Won-Jung Koh; Chang Ki Kim; Young Kil Park; Hee Jin Kim
Journal:  Ann Lab Med       Date:  2013-12-06       Impact factor: 3.464

View more
  13 in total

1.  Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Su-Young Kim; Byung Woo Jhun; Seong Mi Moon; Sun Hye Shin; Kyeongman Jeon; O Jung Kwon; In Young Yoo; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Gee Young Suh; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

3.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

4.  MALDI Spectra Database for Rapid Discrimination and Subtyping of Mycobacterium kansasii.

Authors:  Jayaseelan Murugaiyan; Astrid Lewin; Elisabeth Kamal; Zofia Bakuła; Jakko van Ingen; Vit Ulmann; Miren J Unzaga Barañano; Joanna Humięcka; Aleksandra Safianowska; Uwe H Roesler; Tomasz Jagielski
Journal:  Front Microbiol       Date:  2018-04-03       Impact factor: 5.640

5.  Therapy for Mycobacterium kansasii Infection: Beyond 2018.

Authors:  Michelle S DeStefano; Carolyn M Shoen; Michael H Cynamon
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640

6.  Whole genome sequence of Mycobacterium kansasii isolates of the genotype 1 from Brazilian patients with pulmonary disease demonstrates considerable heterogeneity.

Authors:  Edson Machado; Sidra Ezidio Gonçalves Vasconcellos; Camillo Cerdeira; Lia Lima Gomes; Ricardo Junqueira; Luciana Distasio de Carvalho; Jesus Pais Ramos; Paulo Redner; Carlos Eduardo Dias Campos; Paulo Cesar de Souza Caldas; Ana Paula Chaves Sobral Gomes; Telma Goldenberg; Fatima Fandinho Montes; Fernanda Carvalho de Queiroz Mello; Vinicius de Oliveira Mussi; Elena Lasunskaia; Dick van Soolingen; Antonio Basílio de Miranda; Leen Rigouts; Bouke C de Jong; Conor J Meehan; Marcos Catanho; Philip N Suffys
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-06-25       Impact factor: 2.743

7.  A case of multidrug-resistant Mycobacterium simiae in an elderly woman.

Authors:  Hadi Lotfi; Ehsan Aryan; Mojtaba Sankian; Zahra Meshkat; Ahmad Khalifeh Soltani; Amir Hooshang Alvandi; Hadi Farsiani
Journal:  Respirol Case Rep       Date:  2021-02-01

8.  Determination of Clinical Characteristics of Mycobacterium kansasii-Derived Species by Reanalysis of Isolates Formerly Reported as M. kansasii.

Authors:  Young-Gon Kim; Hong Yeul Lee; Nakwon Kwak; Jae Hyeon Park; Taek Soo Kim; Man Jin Kim; Jee-Soo Lee; Sung-Sup Park; Jae-Joon Yim; Moon-Woo Seong
Journal:  Ann Lab Med       Date:  2021-09-01       Impact factor: 3.464

9.  Genomic Insights Into the Mycobacterium kansasii Complex: An Update.

Authors:  Tomasz Jagielski; Paulina Borówka; Zofia Bakuła; Jakub Lach; Błażej Marciniak; Anna Brzostek; Jarosław Dziadek; Mikołaj Dziurzyński; Lian Pennings; Jakko van Ingen; Manca Žolnir-Dovč; Dominik Strapagiel
Journal:  Front Microbiol       Date:  2020-01-15       Impact factor: 5.640

10.  Ethambutol-resistant Mycobacterium kansasii cervical lymphadenitis in an immunocompetent adult patient: A case report and literature review.

Authors:  Víctor Asensi; Juan J Palacios; Maria Rivas-Carmenado; Tomás Suárez-Zarracina; Enrique Garcia-Carus; Luis M Fernández; Héctor E Torres; Joshua Fierer; José A Carton
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.